Promoting blood circulation drugs mechanism of anti-hepatic fibrosis research.docVIP

Promoting blood circulation drugs mechanism of anti-hepatic fibrosis research Keywords: cirrhosis of the liver stasis agent Review literature Liver fibrosis is the development of a variety of chronic liver injury of liver cirrhosis only way, is a Chinese medicine Xie Tong, product areas such as epilepsy syndrome present, many scholars believe that the basic pathogenesis of liver fibrosis is hepatic blood stasis, blood stasis degree and extent of liver fibrosis is closely related to the use of blood circulation in recent years, based on traditional Chinese medicine for treatment, and achieved good results. A mechanism of liver fibrosis produced Still believe that hepatic stellate cells (HSC) in liver fibrosis play an important role. Play a role in liver fibrosis are two kinds of factors, namely promoting factor and inhibiting factors. Promoting factor with transforming growth factor (TGFβ), platelet-derived growth factor (PDEF), activin, leptin, connective tissue growth factor (CTGF). Inhibitory factor with interferon (IFN), including α-IFN and γ-IFN and interleukin -10 (IL-10) and so on, and inflammation play an important role in HSC activation, and a variety of cells, including HSC adjacent sinus endothelial cells, Kupffer cells, liver cells and white blood cells were involved in HSC activation process [1]. The role of various risk factors, the rest of the HSC was activated, followed by activation of HSC can also produce TGFβ and basic fibroblast growth factor (bFGF) [2], autocrine factor to maintain self-activation and proliferation, transformation for fibroblasts (ASMA), synthesis and secretion of extracellular matrix (ECM) increases, while a large number of synthesis and release of matrix metalloproteinase inhibitors (TIMPS), so that matrix collagenase (MMP) such as protease-activated decreased, ECM degradation reduced , leading to ECM accumulation and the occurrence of liver fibrosis and even cirrhosis of the liver.